Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Pulsed Field Ablation in Three Different Substrate Ablation Strategies for Persistent Atrial Fibrillation
Not Applicable
Not yet recruiting
- Conditions
- Atrial Fibrillation (AF)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT06739512
- Locations
- 🇨🇳
No. 241, West Huaihai Road, Shanghai, Shanghai, China
Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Immune checkpoint inhibitor
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06730503
- Locations
- 🇨🇳
Xiaomin Niu, Shanghai, Shanghai, China
Sd-RAB for the Diagnosis of PPLs
Not Applicable
Not yet recruiting
- Conditions
- Peripheral Pulmonary Lesions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06719687
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06709417
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
Phase 2
Recruiting
- Conditions
- Lung Cancer, Small Cell
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06698965
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
Phase 1
Not yet recruiting
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06690671
- Locations
- 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai 200030, Shanghai, Shanghai, China
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
Phase 2
Not yet recruiting
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06688656
- Locations
- 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai, China
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
Phase 1
Recruiting
- Conditions
- Lung Cancer (NSCLC)Leptomeningeal Metastasis
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT06663306
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus (T2DM)Atrial Fibrillation (AF)
- Interventions
- Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 174
- Registration Number
- NCT06660134
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06659042
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath